BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32125188)

  • 1. Leptin levels are not affected by enalapril treatment after an uncomplicated myocardial infarction, but associate strongly with changes in fibrinolytic variables in men.
    Eriksson MA; Söderberg S; Nilsson TK; Eriksson M; Boman K; Jansson JH
    Scand J Clin Lab Invest; 2020 Jul; 80(4):303-308. PubMed ID: 32125188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
    Boman KO; Jansson JH; Nyhlén KA; Nilsson TK
    Thromb Haemost; 2002 Feb; 87(2):311-6. PubMed ID: 11859853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
    Pedersen OD; Gram J; Jeunemaitre X; Billaud E; Jespersen J
    Coron Artery Dis; 1997 May; 8(5):283-91. PubMed ID: 9285181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction.
    Soejima H; Ogawa H; Yasue H; Suefuji H; Kaikita K; Nishiyama K
    Clin Cardiol; 1997 May; 20(5):441-5. PubMed ID: 9134274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.
    Jansson JH; Boman K; Nilsson TK
    Eur J Clin Pharmacol; 1993; 44(5):485-8. PubMed ID: 8359188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
    Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
    Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-related differences in the associations between hyperleptinemia, insulin resistance and dysfibrinolysis.
    Eriksson MA; Rask E; Johnson O; Carlström K; Ahrén B; Eliasson M; Boman K; Söderberg S
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):625-32. PubMed ID: 18832901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.
    Vaughan DE; Rouleau JL; Ridker PM; Arnold JM; Menapace FJ; Pfeffer MA
    Circulation; 1997 Jul; 96(2):442-7. PubMed ID: 9244210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
    Goodfield NE; Newby DE; Ludlam CA; Flapan AD
    Circulation; 1999 Jun; 99(23):2983-5. PubMed ID: 10368114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
    Wright RA; Flapan AD; Alberti KG; Ludlam CA; Fox KA
    J Am Coll Cardiol; 1994 Jul; 24(1):67-73. PubMed ID: 8006284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
    Thøgersen AM; Söderberg S; Jansson JH; Dahlén G; Boman K; Nilsson TK; Lindahl B; Weinehall L; Stenlund H; Lundberg V; Johnson O; Ahrén B; Hallmans G
    Eur J Cardiovasc Prev Rehabil; 2004 Feb; 11(1):33-40. PubMed ID: 15167204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
    Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
    J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
    Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
    Thögersen AM; Jansson JH; Boman K; Nilsson TK; Weinehall L; Huhtasaari F; Hallmans G
    Circulation; 1998 Nov; 98(21):2241-7. PubMed ID: 9826309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
    Tofler GH; Massaro J; O'Donnell CJ; Wilson PWF; Vasan RS; Sutherland PA; Meigs JB; Levy D; D'Agostino RB
    Thromb Res; 2016 Apr; 140():30-35. PubMed ID: 26896607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
    Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
    Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors.
    Minai K; Matsumoto T; Horie H; Ohira N; Takashima H; Yokohama H; Kinoshita M
    J Am Coll Cardiol; 2001 May; 37(6):1565-70. PubMed ID: 11345366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.